New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2012
07:45 EDTAEGRAegerion announces Boxed Warning for newly-FDA approved Juxtapid
Juxtapid contains a Boxed Warning citing the risk of hepatic toxicity. The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia, or HoFH, who do not have HoFH. The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined. The safety and effectiveness of Juxtapid have not been established in pediatric patients. The FDA based its approval of Juxtapid on Aegerion's pivotal Phase III study, which evaluated the safety and effectiveness of the medicine to reduce LDL-C levels in 29 adult patients with HoFH. In this study, Juxtapid was initiated at 5 mg daily and gradually escalated to doses of 10 mg, 20 mg, 40 mg, up to 60 mg, based on tolerability and acceptable liver enzymes levels. The most common adverse reactions in the Phase III trial were gastrointestinal. Adverse reactions included diarrhea, nausea, vomiting, dyspepsia and abdominal pain. Other common adverse reactions included weight loss, abdominal discomfort, abdominal distension, constipation, flatulence, increased ALT, chest pain, influenza, nasopharyngitis, and fatigue. Elevations in liver enzymes and hepatic fat were also observed.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2014
10:56 EDTAEGRFed calls small cap social media, biotech valuations 'stretched'
The Board of Governors of the Federal Reserve in its Monetary Policy Report dated today said valuation metrics in "some sectors" appear substantially stretched, "particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year." A later part in the document reads, "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The specific targeting of sectors by the Fed seems to be having an impact on stocks in the social media and biotech spaces. Shares of Yelp (YELP) are down over 5% to $67.51, while Twitter (TWTR) and Facebook (FB) are each down 2%. Celgene (CELG) and Amgen (AMGN) are leading the biotech space lower with pullbacks of greater than 1%.
July 11, 2014
11:31 EDTAEGROptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN
July 10, 2014
06:06 EDTAEGRWestfield Capital Management reports 10.88% passive stake in Aegerion
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use